Company ProfilePremium

Mitsubishi Gas Chemical Company, Inc.

Company Profile Analysis

Ticker: 4182.T三菱瓦斯化学株式会社

ESOMAR 23 Corporate BadgeISO Certifications Badge
Mitsubishi Gas Chemical Company, Inc. - Company showcase

Year Founded & Workforce

1951

8,319 Employees

Mitsubishi Gas Chemical Company, Inc. logo

Mitsubishi Gas Chemical Company, Inc. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Mitsubishi Gas Chemical Company, Inc. Overview

Mitsubishi Gas Chemical is a mid-cap Japanese chemical company that has spent four decades migrating from natural-gas-derived commodity chemistry (methanol, ammonia derivatives, xylenes) toward proprietary functional and electronic materials. It is a Mitsubishi-group company but not a subsidiary of any Mitsubishi entity; its share register is dominated by trust banks, life insurers and agricultural cooperatives. Its crown jewels are BT (bismaleimide-triazine) laminate materials for semiconductor package substrates, in which MGC is widely regarded as the category originator, the fast-growing OPE® substrate material for AI servers, ultra-pure hydrogen peroxide and functional chemicals for semiconductor fabs, optical resin polymers for smartphone camera lenses, and MXDA-based specialty aromatics. These sit alongside a cyclical but strategically important equity-accounted methanol network (Saudi Arabia, Brunei, Venezuela, Trinidad & Tobago). In FY2025 MGC booked ¥78.4bn of impairments and its first net loss since FY2012, triggering a sharper portfolio restructuring under the "Grow UP 2026" plan.


What the company does — company's own description (paraphrased from Yuho FY2025)

MGC organizes its group into two reportable segments plus "Other". The Green Energy & Chemicals Division (GEC) manufactures and sells methanol, methanol- and ammonia-based chemicals, life-science products, general-purpose and specialty aromatic chemicals, foamed plastics (through equity affiliate JSP) and electricity. The Functional Chemicals Division (FC) manufactures and sells inorganic chemicals (hydrogen peroxide and semiconductor-grade chemicals), engineering plastics, optical materials, electronic materials and oxygen absorbers. "Other" captures purchased-goods trading not attributed to either segment. The company's mission statement is "creating value to share with society", and its 2030 Vision centres on chemistry-driven social value and sustainable growth.

Business model and revenue model

Revenue / income streamNatureWhere it shows upMateriality
Product salesChemicals, resins, laminates, consumables sold under supply contracts and spotNet salesc.100% of net sales
Equity-method incomeShare of profit of methanol JVs (Saudi Arabia, Brunei, Venezuela, Trinidad & Tobago), JSP, Korea Engineering Plastics, etc.Non-operating income (ordinary profit)¥17.5bn FY2022, –¥5.7bn FY2023, ¥11.0bn FY2024, ¥1.5bn FY2025
Technology licensingNon-exclusive licences for methanol/DME technology (METOR, Brunei Methanol, Caribbean Gas Chemical); PC technology licence to Shanghai subsidiary with running royaltyRoyalty/one-time fees; largely intra-group or embedded in equity income—
Electricity / energyLNG-fired and geothermal power sales, natural gas, iodineNet sales (GEC)—
Contract manufacturingAntibody drug CDMO via JV Cultivecs (1,000L and 2,000L bioreactors)Equity/affiliate—

MGC's revenue is overwhelmingly product sales (B2B chemicals and materials). Material secondary income streams are:

There is no subscription revenue. The business model therefore combines (i) asset-heavy commodity chemistry whose profit is highly sensitive to methanol and polycarbonate spreads, with (ii) IP-protected specialty materials sold on specification into qualified customer processes (substrate makers, fabs, lens makers) where switching costs are high.

Value-chain position

Upstream / feedstock: Owns natural gas and iodine production in Niigata (Toho Earthtech), geothermal stakes (Yuzawa Geothermal, Appi Geothermal), and equity in overseas gas-to-methanol plants. Buys xylene, energy and raw materials externally (Yuho risk section).

Midstream: Methanol, ammonia derivatives (methylamines, DME, MMA products), xylene separation/isomerization (own technology since 1968), MXDA, aromatic aldehydes, polyols, hydrogen peroxide.

Downstream materials: BT laminate and prepreg materials, OPE®, ultra-pure H2O2 and HBC functional chemicals, Iupizeta EP optical polymers, lens monomers, Iupilon PC and Iupital POM, AGELESS oxygen absorbers.

  • MGC rarely sells to consumers; nearly all customers are industrial converters.

Customer types and end-markets

End-marketProductsCustomer type
Semiconductors / ICTBT materials, OPE®, ultra-pure H2O2, HBC chemicals, LE SHEET drilling entry boardsIC substrate makers, PCB makers, semiconductor fabs (Japan, Taiwan, Korea, US, Singapore, China)
Smartphones / optics / AR-VR / automotive sensorsIupizeta EP optical resin polymers, spectacle lens monomersCamera-lens molders, ophthalmic lens makers
Automotive / mobilityMXDA derivatives, MX-Nylon, LEXTER bio-polyamide, PC, POM, mPPETier-1 component makers, coatings/epoxy formulators
Packaging / food / pharmaMX-Nylon barrier resins, AGELESS oxygen absorbers, special polyester (baby bottles)Food and pharma packagers
Chemicals / coatingsMethanol, formaldehyde, MMA products, polyols, PIAChemical companies, paint makers (e.g., Kansai Paint is a disclosed customer)
Energy / environmentLNG power, geothermal, iodine (incl. perovskite-solar derivatives), methanol bunkeringUtilities, shipping, specialty chemical users
Healthcare / foodBioPQQ, SAMe yeast, spermidine yeast, lactic acid bacteria, antibody CDMOSupplement makers, biopharma

Independent characterization

MGC is best understood as two companies under one roof. The FC segment (61% of FY2025 external sales but c.95% of FY2025 segment ordinary profit) is a quality specialty-materials franchise geared to semiconductor packaging and AI-server build-outs. The GEC segment (38% of sales) is a methanol-and-aromatics complex whose earnings swing violently with commodity prices and equity-affiliate results: GEC ordinary profit fell from ¥20.5bn in FY2024 to ¥3.9bn in FY2025 after the Trinidad affiliate impairment and MXDA price erosion. The market valuation (P/B c.1.1x) still prices MGC closer to a diversified Japanese chemical company than to a semiconductor-materials pure play; the investment debate is about whether portfolio restructuring can close that gap.

Strategy

Stated strategy — "Grow UP 2026" (FY2024–FY2026)

Two goals, each with three measures (Yuho FY2025):

Goal 1 — Strengthen business portfolio resilience

  1. Focus on "Uniqueness & Presence" (U&P) businesses — formerly "differentiated businesses", redefined as businesses that excel on growth potential, ability to win and sustainability (expectation, economic value, social value).

  2. Create new value through innovation — target domains ICT, mobility, and medical/food.

  3. Restructure "priority management" businesses — polycarbonate, xylene chain/MXDA, formalin and other underperformers; a President-led "Business Portfolio Resilience Task Team" was formed in FY2025.

Goal 2 — Promote sustainability management

  1. Accelerate carbon neutrality (Carbopath™ circular methanol, GHG reduction, Sharebeing products).

  2. Enhance human-capital management.

  3. Materiality management.

Financial targets (FY2026, final plan year) vs. delivery

MetricFY2024 actualFY2025 actualFY2026 company guidance (Aug 2026)FY2026 plan target
Net sales (¥bn)773.5738.2860.0850.0
Operating profit (¥bn)50.845.271.085.0
Operating margin (%)6.66.18.3≥10
Ordinary profit (¥bn)60.351.979.095.0
EBITDA, company definition (¥bn)———150.0
ROE (%)6.9-6.1c.8.5 (analyst estimate from guidance)≥9
ROIC (%)6.43.2—≥8

Plan assumptions: ¥135/US$ and Dubai crude US$80/bbl. Long-term vision: net sales of ¥1.2 trillion by 2030 (2025 Integrated Report summary). Sharebeing (environment-contributing products) sales target: ¥500bn by FY2030.

Capital allocation policy

Shareholder returns: total payout ratio of 50% (including buybacks) as medium-term guide; progressive dividend policy (avoid cuts unless financial soundness is threatened); DOE target 3.0%.

Buybacks: opportunistic (¥10bn in FY2023, ¥15bn in FY2024; none in FY2025).

Cross-shareholdings: annual board review; FY2025 sales of seven listed holdings for ¥6.1bn (e.g., Iwatani fully sold; Mitsubishi Corporation stake cut from 613,200 to 10,200 shares).

Strategic initiatives register (last c.24 months)

DateInitiativeTypeDetail / status
FY2024–FY2025BT materials capacity doubling at MGC Electrotechno (Thailand)Growth capexCompleted Nov 2025
FY2024–FY2025Semiconductor chemicals capacity expansion in TaiwanGrowth capexCompleted; fixed costs weighed on FY2025; impairment recorded at Taiwan subsidiary
FY2024–FY2025Electronic chemicals ("EL chemicals") projects in Japan and overseasGrowth capexReturns delayed per management (Jul 2026 briefing)
FY2025OPE® new manufacturing baseGrowthUnder consideration
FY2025–FY2026New lens-monomer plantGrowthIn progress
FY2025–FY2026Iodine capacity expansionGrowthPlanned
Sep 2025 → Feb 2026Netherlands MXDA plant (MSCN)RestructuringSuspended, impaired ¥50.2bn, discontinued; removal by end-2029
Mar 2026Kashima PC plant (120kt/yr) closureRestructuringOperations end Mar 2028; Iupizeta EP unaffected
FY2024–FY2025Exit from ortho-xylene, phthalic anhydride, plasticizersRestructuringProduction stopped
FY2025PC sheet/film site consolidationRestructuringCompleted
FY2025Structural reforms incl. asset salesCost/portfolioc.¥15bn earnings improvement claimed for FY2025 (Jul 2026 briefing)
Nov 2025Long-term offtake of c.1 mtpa ultra-low-carbon methanol from Pacifico Mexinol (Transition Industries) from 2029DecarbonizationFirst large-scale procurement under Carbopath
FY2025MoU with TRE Holdings on Japan's first commercial-scale green methanol from woody biomass and wasteDecarbonizationMoU
FY2025Methanol dual-fuel carrier "Dai-7 Kozan Maru" (long-term charter from MOL) delivered; ship-to-ship methanol bunkering at Yokohama anchorageDecarbonization / logisticsCompleted
FY2025Equity investment in Gold Hydrogen Ltd (7.14m shares)New business (natural hydrogen)Completed
FY2025Hiratsuka PR-SHIPS research buildingInnovationCompleted
FY2025MPS device co-development with Ehime University; NEDO international geothermal reservoir researchInnovationAgreements concluded
OngoingDX: in-house ML tool "MLAB", supercomputer expansion, IP landscapingProductivityDeployed group-wide
OngoingInternal carbon price ¥10,000/t-CO2 for capex decisionsESGIn force

Products & Services

Launch years, specifications and pricing are generally not disclosed by MGC; they are marked accordingly. Pricing for all products is B2B contract/spot pricing; no list prices are published.

Green Energy & Chemicals Division

Product / brandDescription & capabilitiesTarget customerLaunch / latestPricing model
Methanol (domestic production + JV offtake)Core C1 chemical; produced historically in Niigata and via overseas JVs (Saudi Arabia, Brunei, Venezuela, Trinidad & Tobago). MGC holds proprietary synthesis catalyst and process technology licensed to JVsChemical producers, formaldehyde/MMA makers, fuel and shipping (bunkering)Since 1952 (domestic)Market-linked (Asian contract/spot)
Carbopath™Circular-carbon methanol platform; methanol made from CO2, waste plastics, digestion gas, biomass; pilot at NiigataDecarbonizing chemical, shipping and energy usersBranding launched c.2023—
Ultra-low-carbon methanol offtakec.1 million t/yr from Transition Industries' Pacifico Mexinol project (Mexico), from 2029SameAgreement 6 Nov 2025Long-term SPA; terms not disclosed
Ammonia, methylamines, DMEDerivatives of methanol and ammoniaChemical, agrochemical, aerosol, fuel usersLong-establishedContract
MMA products (methacrylates)Methyl methacrylate-related derivatives; volume growth in FY2025Acrylic resin, coating makersLong-establishedContract/market
Formalin / formaldehyde (MGC Woodchem)Formaldehyde and stabilizers; sales functions transferred to subsidiary 2023–2024Resin, wood adhesive makersRestructured 2023–2024Contract
PolyolsSpecialty polyols from formaldehyde chemistryCoatings, resinsLong-establishedContract
MXDA (meta-xylenediamine)Proprietary aromatic diamine used as epoxy curing agent, isocyanate and polyamide feedstock; MGC is the historic global leader. European plant project cancelled Feb 2026Coatings, composites, nylon makersLong-establishedContract; under price pressure
1,3-BAC and related derivativesHydrogenated MXDA derivative (curing agents, isocyanates)Coatings, optical resin makers—Contract
Aromatic aldehydesFragrance intermediates and resin additivesFragrance houses, polymer additive makers—Contract
High-purity isophthalic acid (PIA), meta-xyleneFrom xylene separation at Mizushima; ortho-xylene chain exitedPET/resin producersSince 1968 (xylene separation)Market-linked
MX-NylonGas-barrier polyamide (MXD6) for packaging and engineering applicationsPackaging and auto component makersLong-establishedContract
LEXTER™Bio-based polyamide; growing in automotive and electronic partsAuto/electronic component moldersRecent; expandingContract
Reny™High-performance reinforced polyamide (MXD6-based)Precision parts moldersLong-establishedContract
Special polyesterHigh-heat transparent polyester; adopted in baby bottlesConsumer goods molders—Contract
Cyanate estersHigh-performance thermoset raw material for compositesComposite makers—Contract
Transparent polyimide (Neopulim™)Solvent-soluble, transparent, fully fluorine-free polyimide varnishDisplay/flexible device makers—Contract
Thermoplastic polyimideHigh heat resistance, low dielectric, good moldabilityElectronics—Contract
ENDUREDGE™ prepregsFRP prepregs using MGC resins, developed mainly for the US marketAerospace/industrial composite users—Contract
TETRAD™ epoxyPolyfunctional epoxy resinsComposite, electronicsLong-establishedContract
Natural gas & iodine (Toho Earthtech)Water-soluble natural gas in Niigata with high iodine content; iodine capacity expansion planned; iodine derivatives for perovskite solar cells under developmentUtilities, iodine/pharma/electronics usersLong-establishedMarket-linked
LNG power, geothermal powerLNG-fired generation; geothermal stakes (Yuzawa, Appi)Grid / utilitiesOngoingPower tariffs
CCSStudy of CCS in depleted oil/gas fieldsIndustrial emittersDevelopment—
BioPQQ™ (pyrroloquinoline quinone)Fermentation-derived anti-ageing supplement ingredientSupplement makersLong-establishedContract
SAMe-containing dried yeast; spermidine-containing yeast; lactic acid bacteriaNutritional ingredientsSupplement makers—Contract
Antibody CDMO (Cultivecs JV)Contract manufacturing of investigational and API antibodies in 1,000L/2,000L tanksBiopharmaOperatingContract
Foamed plastics (JSP, equity method)ARPRO and other bead foamsAuto, packagingJSP equity-accounted since FY2023—

Functional Chemicals Division

Product / brandDescription & capabilitiesTarget customerLaunch / latestPricing model
Hydrogen peroxide (industrial)Produced since 1978 at Kashima; also overseas (Indonesia affiliate PT Peroksida Indonesia Pratama)Pulp & paper, chemical, environmental users1,978Contract
PersulfatesProduced at YamakitaElectronics, polymerizationLong-establishedContract
Ultra-pure hydrogen peroxide (ELM series)Semiconductor-grade wet chemical; multi-site supply: Japan, US (Arizona, Oregon, Texas), Singapore, Korea, Taiwan, ChinaSemiconductor fabsSince 1990s (US 1995)Contract, often long-term
Functional chemicals (HBC) and chemical polishing liquidsFront-end to back-end process chemicals; new grades developed globallyFabs, OSATsOngoingContract
Iupilon™ polycarbonateGeneral and specialty PC (flame-retardant, low-impurity). Kashima 120kt/yr plant to close March 2028; supply shifting to overseas sites (Shanghai, Thailand)Electrical/electronics, auto, sheetLong-establishedMarket-linked
PC sheet & film (MGC Filsheet)Hard-coat thermoforming film, optical films; production sites consolidatedDisplay, auto interior, signageRestructured FY2025Contract
CO2-based PC intermediateNEDO Green Innovation Fund project to make PC from CO2—Development—
Iupital™ polyacetal (POM)Via Global Polyacetal, Thai Polyacetal, Korea Polyacetal and Korea Engineering Plastics JV with CelaneseAuto, electronics moldersLong-establishedMarket-linked
Iupiace™ / LEMALLOY™ modified PPEEngineering alloysElectrical/autoLong-establishedContract
MEP (Mitsubishi Engineering-Plastics, 75%)Sales JV with Mitsubishi Chemical for engineering plasticsSameConsolidated Apr 2023—
Iupizeta™ EP optical resin polymerHigh-refractive-index optical resin for smartphone camera lenses; expanding to automotive, AR/VR and sensors; post-consumer recycling technology established with customers. Excluded from Kashima PC closureLens moldersLatest grades ongoingContract
Spectacle lens monomersHigh-index monomers produced at Naniwa and Yokkaichi; bio-mass lens monomer adopted by a major customer; new lens-monomer plant planned/under wayOphthalmic lens makersOngoingContract
BT materialsBismaleimide-triazine copper-clad laminates and prepregs for semiconductor package substrates (memory and logic); dual supply from MGC Electrotechno (Shirakawa, Japan) and MGC Electrotechno (Thailand); Thai capacity doubled (completed Nov 2025)IC substrate makersBT developed 1976; continuous upgradesContract
OPE® substrate materialLow-dielectric substrate material for AI-server boards; FY2025 volume growth above plan; new manufacturing base under considerationServer PCB/substrate makersRamping 2024–2026Contract
High-frequency circuit materials; thin laminates; fine-circuit materialsNext-gen package substrate materialsSubstrate makersDevelopment / rampContract
LE SHEET™Drilling entry/back-up sheet for PCB drillingPCB makersLong-establishedContract
AGELESS™ oxygen absorbersFood freshness, pharmaceutical stability, metal anti-corrosion, cultural property protection; smaller, plastic-reduced and PFAS-compliant productsFood, pharma, museumsSince 1970s (not re-verified)Contract/distributor
Food-loss technologiesSpace-control and sterilization technology for meat and produceFood distributorsDevelopment—
QOL Innovation Center ShirakawaOxygen absorber production and plant-factory vegetable cultivation (incl. wasabi cultivation R&D)FoodOngoing—
Microphysiological System (MPS) devicesOrgan-on-chip for drug discovery, co-developed with Ehime UniversityPharma R&DDevelopment (FY2025 agreement)—

Financial Narrative

All figures consolidated, J-GAAP, ¥ million unless stated. FY2021 = year ended 31 Mar 2022 … FY2025 = year ended 31 Mar 2026. Sources: Yuho FY2024 and FY2025; tanshin; S&P Global Market Intelligence (via StockAnalysis) for line items not in the Yuho summary; ENVALITH cross-check. EBITDA = operating income + depreciation & amortization (analyst calculation; MGC's own medium-term-plan EBITDA definition is ordinary profit + interest expense + depreciation, which is higher).

Income statement

Diluted EPS equals basic (no dilutive securities per Yuho). FY2021 DPS of ¥80 per Yuho parent-company table.

Margins

Revenue CAGR: FY2021→FY2025 (4 years) +1.1% p.a.; FY2020→FY2025 (5 years, from ¥595,718m) +4.4% p.a. (analyst calculation). The five-year figure is flattered by the FY2021 post-COVID rebound and depressed by the FY2023 JSP deconsolidation.

Balance sheet (year-end)

Debt definitions: S&P-standardized total debt (including leases) is ¥224.3bn at Mar 2026; MGC's own Yuho states interest-bearing debt of ¥229.2bn. The discrepancy reflects classification differences. At Mar 2026 bonds outstanding were ¥55.0bn (all long-term, after redemption of ¥10.0bn) and long-term loans ¥102.4bn.

Ratios

ROE per Yuho; other ratios are analyst calculations on year-end balances. ROIC (company definition: (operating income – taxes + equity-method income) / invested capital): FY2024 6.4%, FY2025 3.2% (Yuho FY2025); earlier years not disclosed in the documents reviewed. S&P's standardized TTM ROIC (Jun 2026) is 7.18%, a different definition.

Quarterly cadence

Q1 FY2026 net sales, operating income and net income are rounded figures (¥223.7bn, ¥27.8bn, ¥18.3bn) from the Q1 tanshin summary; ordinary profit ¥29,187m is exact (Kabuyoho/IFIS).

Commentary on trends, inflections and drivers

Revenue. Sales peaked at ¥813.4bn in FY2023 and declined two years running. FY2024's –4.9% was largely mechanical (JSP deconsolidation from Q3 FY2023), while FY2025's –4.6% reflects genuine price pressure in methanol, PC and MXDA plus exit from the ortho-xylene chain, partly offset by electronic materials. Q1 FY2026 sales jumped 25.7% YoY on higher methanol prices (Middle East tensions), strong electronic materials and a weaker yen.

Operating profit. Operating income has been range-bound at ¥45–55bn for five years despite cumulative capex of c.¥362bn — the central problem the market is pricing. FY2021's ¥55.4bn high reflected the post-COVID chip and commodity boom; FY2023's ¥47.3bn low reflected the methanol/PC downturn. FY2025 operating income of ¥45.3bn was hit by MXDA competition and fixed-cost step-ups at the Taiwan semiconductor-chemicals site. Q1 FY2026 operating income of ¥27.8bn (+153.5%) is the strongest quarterly print in the period and annualizes above the full-year guidance of ¥71bn.

Ordinary profit and equity income. Equity-method income is the swing factor: it ranged from +¥17.5bn (FY2022) to –¥5.7bn (FY2023, when methanol affiliates suffered). FY2025's ¥1.5bn included an impairment at the Trinidad methanol affiliate. In Q1 FY2026, equity income fell to ¥0.5bn from ¥2.3bn because of reduced operation at the Saudi methanol producer amid regional tensions — a reminder that methanol price upside does not always flow through to MGC's affiliates.

Net income. The FY2025 loss of ¥40.3bn was driven by ¥78.4bn of impairments (Netherlands MXDA ¥50.2bn; Taiwan semiconductor-chemicals subsidiary c.¥10.6bn; China subsidiary; PC-related assets) and a ¥18.1bn tax charge on a pre-tax loss (non-deductibility of impairments). Extraordinary income of ¥14.7bn included ¥9.0bn of fixed-asset sale gains and ¥4.9bn of securities gains.

Balance sheet. Net debt rose from ¥5.6bn (Mar 2022) to ¥155.3bn (Mar 2026) as negative free cash flow combined with ¥86bn of dividends and ¥32bn of buybacks over five years. Net debt/EBITDA of 1.8x remains moderate and the equity ratio is 58%, but the trend — five consecutive years of negative FCF — is the clearest financial weakness. Inventory days lengthened from c.105 to c.131, adding working-capital drag.

Cash flow. Operating cash flow stepped up to c.¥74–75bn from FY2023, but capex of ¥77–85bn absorbed it. Capex guidance of ¥61bn for FY2026 and lower depreciation after impairments should allow FCF to turn positive in FY2026 for the first time in the period (analyst inference, not company guidance).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentBusiness units (事業部)Key productsKey consolidated / equity entities

Green Energy & Chemicals (GEC)

C1 Chemicals; High Performance Products; Energy Resources & Environment; Life Science

Methanol, ammonia derivatives, DME, methylamines, MMA products, formalin, MXDA, aromatic aldehydes, polyols, MX-Nylon, special polyester, cyanate, polyimides, high-purity isophthalic acid, xylene isomers, natural gas, iodine, LNG power, geothermal, PQQ/SAMe

MGC Next, MGC Terminal, Toho Earthtech, MGC Specialty Chemicals Netherlands (MSCN), MGC Energy, MGC Woodchem; equity: Japan-Saudi Arabia Methanol, METOR, Brunei Methanol, Japan Trinidad Methanol, JSP, Yuzawa Geothermal, Appi Geothermal, Kokka Sangyo

Functional Chemicals (FC)

Inorganic Chemicals; Synthetic Resins (engineering plastics); Optical Materials; Electronic Materials; Life & Hygiene Solutions

H2O2, persulfates, ultra-pure H2O2, HBC chemicals, Iupilon PC, Iupital POM, mPPE, PC sheet/film, Iupizeta EP, lens monomers, BT materials, OPE®, AGELESS

Taixing Ling Su (China), Samyoung Pure Chemicals (Korea, 51%), MGC Pure Chemicals America, MGC Pure Chemicals Singapore, Ju-Ling Precision Chemical (Taiwan), MGC Filsheet, Global Polyacetal, Thai Polyacetal, Korea Polyacetal, MGC Engineering Plastics (Shanghai), MGC Electrotechno, MGC Electrotechno (Thailand), MEP (75%), Thai Polycarbonate, Ageless (Thailand); equity: Korea Engineering Plastics, MGC Otsuka Chemical, Taifong PCB (Taiwan), Samyang Kasei

Other

Purchased-goods trading not attributable to segments

——

GEC

3502232

FC

4906565

Results by Segment and Segment Margins & Growth (%)

MetricFY2024FY2025

GEC net sales incl. intersegment (JPY Bn)

323.1286.9

GEC operating profit (JPY Bn)

12.75.6

GEC ordinary profit (JPY Bn)

20.53.8

GEC operating margin (%)

3.92.0

FC net sales incl. intersegment (JPY Bn)

444.1448.3

FC operating profit (JPY Bn)

41.343.8

FC ordinary profit (JPY Bn)

43.949.1

FC operating margin (%)

9.39.8

Other net sales (JPY Bn)

19.114.8

Other operating profit (JPY Bn)

1.11.3

Adjustments to sales (JPY Bn)

-12.9-11.8

Adjustments to operating profit (JPY Bn)

-4.4-5.5

Consolidated net sales (JPY Bn)

773.5738.2

Consolidated operating profit (JPY Bn)

50.845.2

Revenue by Segment and Revenue by Segment (%)

MetricFY2024FY2025

GEC external sales (JPY Mn)

313,392277,904

FC external sales (JPY Mn)

443,563447,999

Other external sales (JPY Mn)

16,47412,339

GEC share of consolidated sales (%)

40.537.6

FC share of consolidated sales (%)

57.360.7

Other share of consolidated sales (%)

2.11.7

Segment Assets & Liabilities and Results by Segment

MetricFY2024FY2025

GEC segment assets (JPY Mn)

464,140415,814

GEC depreciation (JPY Mn)

13,75113,217

GEC equity-method income (JPY Mn)

8,035-807

GEC impairment loss (JPY Mn)

25856,145

GEC investment in equity-method affiliates (JPY Mn)

140,689143,348

Segment Revenue

ItemGECFCOther / CorporateTotal

Capex FY2025 (JPY Mn)

24,64442,564

98 / 4,614

71,922

Capex plan FY2026 (JPY Mn)

14,00043,0004,00061,000

R&D expense FY2025 (JPY Mn)

10,88515,750—26,636

Consolidated employees 31 Mar 2026

2,6325,090

106 / 491

8,319

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Net sales (JPY Mn)

705,656781,211813,417773,591738,243

Sales growth YoY (%)

18.510.74.1-4.9-4.6

Gross profit (JPY Mn)

162,586168,180173,190164,293161,362

SG&A (JPY Mn)

107,225119,149125,852113,442116,068

Operating income (JPY Mn)

55,36049,03047,33750,85145,293

Depreciation & amortization (JPY Mn)

32,39533,97038,23336,40639,863

EBITDA (JPY Mn, OI + D&A)

87,75583,00085,57087,25785,156

Equity-method income (JPY Mn)

14,88317,546-5,69610,9561,545

Ordinary profit (JPY Mn)

74,15269,76446,04060,31651,947

Extraordinary income (JPY Mn)

6,4244,87620,5683,06714,729

Extraordinary losses (JPY Mn)

10,9474,4025,7227,03782,743

Pre-tax income (JPY Mn)

69,62870,23960,88756,347-16,065

Income taxes (JPY Mn)

17,09815,45014,0725,40918,076

Net income attributable to owners (JPY Mn)

48,29549,08538,81845,544-40,318

EPS basic (JPY)

232.15239.08190.97228.93-207.04

EPS diluted (JPY)

232.15239.08190.97228.93-207.04

Dividend per share (JPY)

80808095100

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Gross margin (%)

23.021.521.321.221.9

Operating margin (%)

7.86.35.86.66.1

EBITDA margin (%)

12.410.610.511.311.5

Ordinary margin (%)

10.58.95.77.87.0

Net margin (%)

6.86.34.85.9-5.5

Balance Sheet and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Total assets (JPY Mn)

928,6511,029,3171,068,0101,119,6881,113,040

Cash & deposits (JPY Mn)

102,049108,37871,44768,24668,966

Cash & cash equivalents per CF statement (JPY Mn)

92,257101,18565,39756,98559,096

Short-term debt incl. current bonds (JPY Mn)

38,92547,91351,81885,61764,240

Long-term debt: bonds + LT loans (JPY Mn)

66,62194,68099,671114,441157,439

Total debt incl. leases (JPY Mn)

107,648146,943155,001202,976224,267

Net debt (JPY Mn)

5,59338,47283,554134,730155,301

Total net assets (JPY Mn)

630,887671,249684,832697,375679,550

Shareholders' equity excl. minorities (JPY Mn)

568,766607,613657,745668,222646,417

Goodwill (JPY Mn)

4,8114,42516,86815,31013,751

Other intangibles (JPY Mn)

6,4797,5558,0039,6859,794

Inventories (JPY Mn)

155,669178,142200,529207,526206,983

Working capital (JPY Mn)

253,241262,807221,668185,339220,667

Equity ratio (%)

61.2559.0361.5959.6858.08

Book value per share (JPY)

2,733.862,970.073,284.963,431.903,319.36

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Cash Flow

MetricFY2021FY2022FY2023FY2024FY2025

Operating cash flow (JPY Mn)

52,09055,22273,47375,44074,726

Capital expenditure (JPY Mn)

56,34762,72180,81585,36676,731

Free cash flow (JPY Mn)

-4,257-7,499-7,342-9,926-2,005

Investing cash flow (JPY Mn)

-64,954-64,071-76,172-90,994-61,311

Financing cash flow (JPY Mn)

-3,6667,996-40,6894,707-14,364

Dividends paid (JPY Mn)

16,64215,46416,36717,02119,472

Share buybacks (JPY Mn)

57,08310,00515,0067

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2021FY2022FY2023FY2024FY2025

ROE (%)

8.848.356.146.87-6.13

ROA (NI / avg assets, %)

5.24.83.64.1-3.6

Current ratio (x)

2.272.191.921.671.96

Total debt / net assets (x)

0.170.220.230.290.33

Net debt / EBITDA (x)

0.060.460.981.541.82

Interest coverage, OI / interest expense (x)

64.528.118.521.416.8

Asset turnover, sales / avg assets (x)

0.800.800.780.710.66

Days sales outstanding (days)

90.682.274.074.173.4

Days inventory outstanding (days)

104.6106.1114.3124.3131.0

Days payables outstanding (days)

62.152.662.261.858.2

Cash conversion cycle (days)

133.1135.7126.2136.6146.2

Income Statement

MetricQ1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026

Net sales (JPY Mn)

177,977183,701187,783188,782223,700

Operating income (JPY Mn)

10,98214,16312,6597,48927,800

Ordinary profit (JPY Mn)

13,83017,65016,6913,77629,187

Net income (JPY Mn)

8,405-36,3441,779-14,15818,300

Region Overview

RegionMain consolidated production assetsSegment

Japan

Niigata, Mizushima, Yokkaichi, Yamakita, Kashima, Naniwa plants; MGC Electrotechno Shin-Shirakawa; Toho Earthtech; MGC Ageless Shirakawa

Both

Thailand

MGC Electrotechno (Thailand) (BT; doubled capacity Nov 2025), Thai Polyacetal, Thai Polycarbonate, Ageless (Thailand)

FC

Korea

Samyoung Pure Chemicals (ultra-pure H2O2), Korea Polyacetal

FC

China

MGC Engineering Plastics (Shanghai) (PC), Taixing Ling Su (electronic chemicals)

FC

Taiwan

Ju-Ling Precision Chemical, Taichung (semiconductor chemicals; impaired FY2025)

FC

United States

MGC Pure Chemicals America: Arizona, Oregon, Texas

FC

Singapore

MGC Pure Chemicals Singapore

FC

Netherlands

MSCN Rotterdam (MXDA; construction discontinued, removal by end-2029)

GEC

Equity affiliates

Saudi Arabia, Brunei, Venezuela, Trinidad & Tobago (methanol); Indonesia (H2O2); Korea (KEP); Taiwan (Taifong PCB)

Both

Capital Markets Data (JPY) and Valuation Multiples (x)

MetricFY2021FY2022FY2023FY2024FY2025

Fiscal-year high (JPY)

2,8232,2342,685.53,3705,446

Fiscal-year low (JPY)

1,8421,7661,8992,1311918

P/E at fiscal year-end (x)

8.968.2113.5610.160

Total shareholder return, 5-yr cumulative index (%)

79.678.2104.398.0148.5

TOPIX incl. dividends, same basis (%)

102.0107.9152.5150.2202.2

Valuation Multiples

MultipleMGCSource

Market cap

¥748.8bn

S&P/StockAnalysis

EV

¥934.1bn

S&P/StockAnalysis

P/E (trailing)

n/m (loss)

—

P/E (forward, consensus)

15.5x

S&P/StockAnalysis

P/E (company forecast)

13.3–13.4x

Kabuyoho/Monex

EV/EBITDA (TTM)

9.25x

S&P/StockAnalysis

EV/Sales (TTM)

1.19x

S&P/StockAnalysis

P/B

1.07–1.11x

S&P; Kabuyoho

Dividend yield

2.82–2.93%

S&P; Kabuyoho

Per-Share Data and Dividends & Capital Returns

MetricFY2021FY2022FY2023FY2024FY2025FY2026

Dividend per share (JPY)

80808095100110

Dividends paid (JPY Mn)

16,64215,46416,36717,02119,47221,400

Resolution Date Details

Resolution dateMax sharesMax valuePeriodExecutedCancellation

8 Nov 2023

5,000,000 (2.44%)

¥10.0bn

9 Nov 2023 – 31 Jan 2024

Completed

5,000,000 shares cancelled 31 Jan 2024

8 Nov 2024

5,600,000 (2.80%)

¥15.0bn

11 Nov 2024 – 24 Mar 2025

5,552,600 shares, ¥14.9998bn

Cancelled 31 Mar 2025

Capital Instruments

InstrumentAmount (JPY Mn)Maturity bucket

Short-term borrowings

64,240

< 1 year

Current portion of bonds

0

< 1 year (¥10bn redeemed in FY2025)

Bonds

55,000—

Long-term borrowings

102,439—

Lease obligations

2,588

Mixed

Analyst Conclusions

Management guidance (FY2026, revised 7 Aug 2026)

MetricOriginal guide (13 May 2026)Revised guide (7 Aug 2026)YoY vs FY2025 (revised)
Net sales (¥bn)840860+16.5%
Operating profit (¥bn)5971+56.8%
Ordinary profit (¥bn)6679+52.1%
Net income (¥bn)4655turnaround from –40.3
H1 ordinary profit (¥bn)—46—
DPS (¥)110110+10
Capex (¥bn)61—–15%

Q1 FY2026 delivered 36.9% of full-year ordinary profit guidance. Management noted Middle East effects were limited except at the Saudi site and that cost increases are being passed through, while some product markets remain unstable (Q1 presentation summary).

Consensus growth expectations

Consensus FY2026 ordinary profit of c.¥79.3bn sits essentially on company guidance; consensus 3-year revenue CAGR c.6.7% (S&P). Simply Wall St previously cited c.4.6% p.a. revenue growth (May 2025).

Bull case

  1. Earnings inflection is real: Q1 FY2026 OP of ¥27.8bn (+153.5%) annualizes well above the ¥71bn guide; FC segment profit already rose in a weak FY2025, and AI-server OPE® demand is running ahead of plan.

  2. Clean-up removes drag: ¥78.4bn of impairments, the MSCN exit and the Kashima closure cut depreciation and loss-making exposure; management cites c.¥15bn of reform benefits. FY2026 NI of ¥55bn implies ROE of c.8.5%, close to the ≥9% target.

  3. Valuation and returns: at c.1.1x book and a c.2.8% yield with a progressive dividend, the stock offers downside support; consensus targets imply c.40% upside.

Bear case

  1. Execution credibility: two major overseas projects (MSCN, Taiwan chemicals) were impaired within a year; ROIC was 3.2% in FY2025; FCF has been negative for five consecutive years, and net debt rose to ¥155bn.

  2. Plan miss: even after the upgrade, FY2026 OP guidance (¥71bn) is ¥14bn short of the ¥85bn plan, and the 10% margin target looks out of reach; the plan's ¥135/$ assumption flatters exporters.

  3. Commodity and geopolitical tail risk: equity income collapsed to ¥0.5bn in Q1 FY2026 despite higher methanol prices because of the Saudi outage; Venezuela and Trinidad remain impairment candidates; Chinese overcapacity continues to pressure MXDA, PC and POM.

Catalysts and monitorables (next 12 months)

TimingCatalyst / monitorable
10 Nov 2026Q2 FY2026 results — delivery vs ¥46bn H1 ordinary guide; any further guidance upgrade
H2 FY2026OPE® capacity decision (new base); BT utilization in Thailand
H2 FY2026Xylene-chain restructuring decision following MSCN exit
OngoingSaudi methanol affiliate operating rate; methanol price trajectory
OngoingTaiwan/US semiconductor-chemical utilization and fixed-cost absorption
Feb 2027Q3 FY2026 results
May 2027FY2026 results; launch of the next medium-term plan (post-Grow UP 2026) with new ROIC targets and capital-allocation framework
Any timeResumption of buybacks (none in FY2025) as FCF turns positive
Any timeFurther cross-shareholding disposals

Analyst verdict

Mitsubishi Gas Chemical enters the final year of Grow UP 2026 with a clearer identity than at any point in the past decade. The FY2025 loss was painful but largely non-cash and concentrated in assets that were never central to the company's future: a late-cycle European MXDA plant, an over-built Taiwan chemical site, a sub-scale domestic polycarbonate line and an exposed methanol affiliate. What remains is a functional-materials franchise that generated nearly all of FY2025's segment ordinary profit and that sits squarely in the path of AI-server and advanced-packaging demand, plus a methanol business that is volatile but strategically optioned on decarbonized fuels.

The first quarter of FY2026 validated the recovery thesis faster than consensus expected, and the balance sheet — 58% equity ratio, net debt/EBITDA below 2x — absorbs the write-downs without stress. Valuation at roughly book value and around 13–15x forward earnings does not demand heroic assumptions.

The case against is not about solvency but about stewardship. Five consecutive years of negative free cash flow, an operating profit line stuck between ¥45bn and ¥55bn despite heavy investment, and ROIC far below the cost of capital mean that the market's long-standing discount is earned. The next medium-term plan, due around May 2027, is therefore the pivotal event: investors will want explicit capital-allocation discipline (hurdle rates, capex ceilings, buyback commitments), a decision on the residual xylene chain, and a credible path to the 10% operating margin the current plan will miss.

On balance, we view MGC as a recovery-with-quality-core story whose near-term earnings momentum is strong but whose re-rating depends on proving that FY2025 marked the end, not a pause, in value-destructive capex. Positive near-term skew; conviction contingent on H2 FY2026 delivery and the shape of the next plan.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitleBorn (age at Oct 2026)MGC tenure / key prior rolesShares held

Masashi Fujii

Representative Director, Chairman; Board Chair; chairs Compensation & Nomination Committee

10 Mar 1959 (67)

Joined 1981; organic chemicals business head; Natural Gas Chemicals Company President; Director 2015; President Apr 2019–Mar 2025; Chairman since Apr 2025

51k

Yoshinori Isahaya

Representative Director, President & CEO

18 Apr 1965 (61)

Joined 1991; Tokyo Research Lab head (2019); executive officer, corporate planning (2020–21); managing executive officer, R&D and IP (2023); President since Apr 2025

21k

Motoyasu Kitagawa

Director, Senior Managing Executive Officer — internal control & risk, HR/GA, finance & accounting, CSR/IR (de facto CFO)

2 Apr 1963 (63)

Joined 1986; President, MGC America (2014); corporate planning head (2019)

26k

Ko Mouto (毛戸耕)

Director, Managing Executive Officer — production technology, EHS & QA, raw materials & logistics

5 Feb 1964 (62)

Joined 1988; Mizushima plant manager (2019); R&D (2021)

22k

Tomoyuki Azuma

Director, Managing Executive Officer — R&D and IP

21 Jun 1965 (61)

Joined 1989; Electronic Materials Division head (2019–2025)

12k

Chika Kobayashi

Director, Managing Executive Officer — compliance, corporate planning, internal audit, IT

25 Aug 1966 (60)

Joined 1990; accounting group manager; corporate planning head (2023)

12k

Yasushi Manabe

Outside Director (independent)

15 Dec 1956 (69)

Ex-Hitachi executive officer/CMO; outside director at Nichias

2k

Kazue Kurihara

Outside Director (independent)

24 Jan 1951 (75)

Professor emerita, Tohoku University (surface chemistry); outside director at Hamamatsu Photonics

1k

Chi Sato

Outside Director (independent)

8 Aug 1954 (72)

Career diplomat; ambassador to UNESCO and Hungary

—

Mihoko Manabe

Outside Director (independent; foreign national)

3 Nov 1958 (67)

Moody's (1988–2023), Managing Director at Moody's Japan; outside director at Torii Pharmaceutical

—

Board of Directors — Masato Inari

NameRoleBackground

Masato Inari

Full-time Audit & Supervisory Board Member

Former Representative Director/Senior MEO; ex-Niigata plant head

Nobuhisa Ariyoshi

Full-time A&SB Member

Former Representative Director/Senior MEO (finance, HR, risk)

Mayako Perez Takahashi

Full-time Outside A&SB Member

Audit firm (Deloitte Tohmatsu, KPMG AZSA), JICA, ORIX

Tsuneaki Tejima

Outside A&SB Member

Ex-Nippon Life director; President, NLI Research Institute

Tsuyoshi Watanabe

Outside full-time member — resigned at June 2026 AGM

Ex-MUFG Bank, Nidec

Directors' Remuneration

CategoryTotal (JPY Mn)Base (JPY Mn)Performance-linked (JPY Mn)Restricted stock (JPY Mn)Headcount

Directors (excl. outside)

5183261484210

A&SB members (excl. outside)

5555——3

Outside officers

8686——9

Total

6604681484222

Board & Management Changes

DateChangeContext

1 Apr 2025

Isahaya appointed President; Fujii to Chairman; Kurai steps down from representative role (director until June 2025)

Planned succession announced 3 Feb 2025

Jun 2025 AGM

Outside directors Chi Sato and Mihoko Manabe join; Haruko Hirose and Toru Suzuki leave; Ariyoshi and Perez Takahashi join A&SB

Board refresh

Apr 2026

Azuma's portfolio retitled R&D and IP

Organizational

Jun 2026 AGM

Board reduced to 10; Yamaguchi and Akase leave board; Watanabe resigns from A&SB

Governance streamlining after FY2025 loss

Major Shareholders

RankHolderShares (000)%
1

The Master Trust Bank of Japan (trust account)

21,51611.05
2

Custody Bank of Japan (trust account)

14,7177.56
3

Meiji Yasuda Life Insurance

8,7974.52
4

State Street Bank and Trust Co. 505001

6,5933.39
5

Nippon Life Insurance

5,8583.01
6

National Mutual Insurance Federation of Agricultural Cooperatives (Zenkyoren)

5,7752.97
7

Norinchukin Bank

5,0262.58
8

JPMorgan Securities Japan

4,3722.25
9

MSIP Client Securities

3,5941.85
10

Morgan Stanley MUFG Securities

3,1361.61
—

Top 10 total

79,38940.77

Competitive Landscape

Competitors by Segment

MGC businessNamed competitorsRelative positioning of MGC

BT / IC-package substrate materials

Resonac (ex-Hitachi Chemical/Showa Denko Materials), Panasonic Industry (MEGTRON series, high-speed laminates), Doosan Electro-Materials, Sumitomo Bakelite, Elite Material Co. (EMC), ITEQ, Taiwan Union Technology

Category originator in BT; strong position in memory/logic package substrates.

OPE® / high-frequency server materials

Panasonic Industry, EMC, Doosan, Resonac

Fast-growing challenger; volumes ahead of plan

Ultra-pure H2O2 and wet process chemicals

Solvay, Evonik, Arkema (H2O2); Kanto Chemical, Mitsubishi Chemical, Dongwoo Fine-Chem, Entegris (formulated chemistries)

Global multi-site footprint (US, Asia); Taiwan expansion under-earning

Methanol

Methanex, SABIC (partner), Proman, Chinese coal-to-methanol producers

Mid-size equity-based producer; differentiated by technology licensing and Carbopath

MXDA and derivatives

Chinese producers (unnamed in MGC filings)

Historic technology leader losing price leadership

Polycarbonate

Covestro, SABIC, Teijin, Mitsubishi Chemical (partner in MEP), LG Chem, Lotte Chemical, Wanhua

Sub-scale in commodity PC; retreating (Kashima closure)

POM

Celanese (partner in KEP), Polyplastics, Asahi Kasei, Chinese producers

Mid-tier

Optical resin polymers / lens monomers

Mitsui Chemicals (MR lens monomers, APEL), Teijin, Osaka Gas Chemicals (OKP), Zeon (COP)

Strong in high-index smartphone camera lens polymers

Oxygen absorbers

Multisorb (Filtration Group), Clariant (CSP), various Asian producers

AGELESS is a pioneer brand

Peer Comparison FY2026

CompanyRevenue (JPY Bn)Operating margin (%)ROE (%)Equity ratio (%)Fiscal year basis

Mitsubishi Gas Chemical

773.66.66.959.7

FY ended Mar 2025

Mitsubishi Gas Chemical

738.26.1-6.158.1

FY ended Mar 2026

Mitsubishi Chemical Group

3,7000.80.730.0

Latest per EDINET DB comparison

Asahi Kasei

3,0707.58.050.5

Latest per EDINET DB comparison

Shin-Etsu Chemical

2,57024.710.478.7

Latest per EDINET DB comparison

Sumitomo Chemical

2,3306.56.429.6

Latest per EDINET DB comparison

Japanese chemicals industry median (157 cos.)

—6.96.664.6

EDINET DB

Recent Developments

--

Company Snapshot

$4,931.5M

Revenue

8,319

Employees

1951

Founded

Tokyo /, Japan

Headquarters

SWOT Analysis

Strengths

  • Electronic materials earnings engine: FC segment ordinary profit rose 11.8% to ¥49.1bn in FY2025 while GEC fell 81.2% — FC delivered c.95% of segment ordinary profit (Yuho FY2025).
  • AI-linked growth vector: OPE® volumes for AI servers exceeded plan in FY2025 (Yuho FY2025).
  • Capacity in place: Thai BT capacity doubled in Nov 2025 (MGC release; Chemical Engineering).
  • Balance-sheet resilience: equity ratio 58.1%, net debt/EBITDA 1.8x at Mar 2026 despite ¥78.4bn of impairments (Yuho FY2025; analyst calculation).
  • Stable operating cash generation: OCF ¥73.5–75.4bn in each of the last three years (Yuho).
  • Shareholder-return commitment: progressive dividend raised to ¥100 (FY2025) and ¥110 planned (FY2026) through a loss year; DOE 3% target (Yuho FY2025).
  • Global chemical footprint near fabs: ultra-pure chemical plants in Arizona, Oregon, Texas, Singapore, Korea, Taiwan and China (Yuho FY2025).

Weaknesses

  • Chronic negative free cash flow: FCF negative in each of FY2021–FY2025 (–¥2.0bn to –¥9.9bn) (S&P/StockAnalysis).
  • Capital-allocation misses: ¥50.2bn MSCN impairment; c.¥10.6bn Taiwan subsidiary impairment; management admits delayed returns on EL-chemicals investments (Extraordinary Report Nov 2025; FilingReader; Jul 2026 briefing).
  • Stagnant operating profit: OP ¥45–55bn for five years despite c.¥362bn capex (Yuho; S&P).
  • Low returns: ROIC 3.2% in FY2025 vs ≥8% target; ROE –6.1% (Yuho FY2025).
  • Rising leverage: net debt up from ¥5.6bn to ¥155.3bn in four years (S&P/StockAnalysis).
  • Inventory build: inventory days up from c.105 to c.131 (analyst calculation).
  • Low gender diversity in management: female managers 4.6% of parent managers; 43 vs target 60 (Yuho FY2025).

Opportunities

  • AI/advanced packaging super-cycle lifting BT and OPE® (Q1 FY2026 OP +153.5%) (Q1 FY2026 tanshin summary).
  • Lower depreciation post-impairment improves FY2026+ margins (ENVALITH reading of company commentary).
  • Carbopath / green methanol: 1 mtpa ultra-low-carbon methanol offtake from 2029; TRE Holdings MoU; methanol bunkering (Yuho; roic.ai).
  • Sharebeing ¥500bn 2030 sales target for environment-contributing products (Yuho FY2025).
  • Iodine expansion and perovskite-solar iodine derivatives (Yuho FY2025).
  • Further portfolio pruning (xylene chain review) could lift ROIC structurally (Yuho FY2025).

Threats

  • Methanol and Middle East geopolitics: Saudi methanol affiliate output reduced in Q1 FY2026; equity income fell to ¥0.5bn (Q1 FY2026 summary).
  • Chinese overcapacity in PC, POM, MXDA eroding prices (Yuho FY2025).
  • Semiconductor cyclicality and customer inventory corrections after FY2025 stock-building (Yuho FY2025).
  • FX: plan assumes ¥135/$; yen appreciation would hit export margins and translation (Yuho risk factors).
  • Further impairment risk on overseas plants and affiliates (Yuho risk factor "business investments"; Venezuela exposure).
  • US tariff policy and trade restrictions on chip supply chains (Yuho FY2025 outlook).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
1 Apr 2025Yoshinori Isahaya becomes President & CEO; Masashi Fujii becomes ChairmanGenerational handover to an R&D/strategy-planning executive
12 May 2025FY2024 results: sales ¥773.6bn (–4.9%), OP ¥50.9bn (+7.4%), NI ¥45.5bn (+17.3%); DPS ¥95; FY2025 DPS guided ¥100EPS of ¥229 missed consensus by c.4.7% (Simply Wall St)
15 May 2025Nomura group large-holding report (c.6.1%)Active institutional interest
24–25 Jun 2025FY2024 Yuho filed; AGM elects outside directors Chi Sato and Mihoko ManabeBoard refresh, more international/finance expertise
7 Aug 2025Q1 FY2025: sales ¥178.0bn (–5.4%), OP ¥11.0bn (–30.2%), NI ¥8.4bn (–28.4%)Methanol and PC weakness; BT strong
15–30 Sep 2025Large-holding reports by Sumitomo Mitsui Trust group and Mizuho groupRegister churn
17 Sep 2025Construction of Rotterdam MXDA plant suspendedFirst signal of MXDA strategy reversal
6 Nov 2025Long-term SPA with Transition Industries for c.1 mtpa ultra-low-carbon methanol from 2029Anchors Carbopath supply
10–11 Nov 2025Q2 FY2025: ¥50.2bn impairment at MSCN; H1 net loss ¥27.9bn; Extraordinary Report filedLargest single impairment in company history (analyst view)
Nov 2025Completion of BT-material capacity expansion at MGC Electrotechno (Thailand), doubling capacitySupports AI/advanced-packaging demand
Nov 2025Interim dividend ¥50 resolved (10 Nov)Progressive dividend maintained despite losses
Feb 2026Q3 FY2025: 9-month net loss ¥26.2bn; cumulative impairments c.¥59.4bn (Netherlands, China); full-year NI forecast revised to a ¥18bn lossGuidance cut. Note: one secondary source describes the prior forecast as an ¥18.0bn profit; the Q3 forecast was a loss — discrepancy noted
20 Feb 2026Board decides to discontinue MSCN MXDA construction; removal by end-2029Exit finalized
Mar 2026Middle East escalation (Strait of Hormuz disruption cited in Yuho) lifts energy/methanol prices and disrupts raw materialsMixed: methanol price tailwind vs. Saudi affiliate disruption
23 Mar 2026MUFG group large-holding report (c.5.4%)Register churn
31 Mar 2026Decision to close Kashima PC plant (120kt/yr) by Mar 2028Structural reform of "priority management" business
Apr 2026Executive portfolio realignments (e.g., Azuma: R&D & IP)Organizational
13 May 2026FY2025 results: sales ¥738.2bn (–4.6%), OP ¥45.3bn (–10.9%), NI –¥40.3bn; impairments ¥78.4bn incl. c.¥10.6bn at Taiwan semiconductor-chemicals subsidiary; PC restructuring loss c.¥5.3bn; Trinidad affiliate loss c.¥4.2bn; FY2026 guidance sales ¥840bn, OP ¥59bn, ordinary ¥66bn, NI ¥46bn; DPS ¥110 plannedKitchen-sink year; dividend raised regardless
13 May 2026Executive pay cuts: Chairman and President –30% for 3 months from Jul 2026; others –10% to –20%Accountability signal
26 May 2026Year-end dividend ¥50 resolved (FY2025 total ¥100)Progressive policy
22 Jun 2026FY2025 Yuho filedPrimary disclosure
25 Jun 2026AGM: board reduced to 10 members; outside director share rises to 40%Governance streamlining
3 Jul 2026Management briefing: reiterates Grow UP 2026 targets (¥850bn sales, ¥85bn OP, ROE ≥9%, ROIC ≥8%); acknowledges delayed returns on EL-chemicals investments; c.¥15bn earnings improvement from reformsCredibility test for FY2026
Jul 2026Share price c.¥4,383 (24 Jul) — near multi-year highs after FY2025 troughMarket looks through impairments
7 Aug 2026Q1 FY2026: sales ¥223.7bn (+25.7%), OP ¥27.8bn (+153.5%), ordinary ¥29.2bn (+111.0%; 59% above IFIS consensus of ¥18.3bn), NI ¥18.3bn (+118.1%); full-year guidance raised to sales ¥860bn, OP ¥71bn, ordinary ¥79bn, NI ¥55bn; H1 ordinary guide ¥46bnStrong inflection; equity income hit by Saudi methanol plant outage
19 Aug 2026Share price falls c.6% to c.¥3,756 intradayProfit-taking / sector rotation (cause not disclosed)
29 Sep 2026Ex-dividend date for interim dividend—
10 Nov 2026 (scheduled)Q2 FY2026 resultsNext catalyst

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Income Statement: Revenue & Gross Profit: Net sales rose from JPY 705.7 Bn in FY2021 to JPY 738.2 Bn in FY2025.
Mitsubishi Gas Chemical Company, Inc. — Income Statement: Revenue & Gross Profit
Series (JPY Bn)FY2021FY2022FY2023FY2024FY2025
Net sales705.7781.2813.4773.6738.2
Gross profit162.6168.2173.2164.3161.4

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. MGC Annual Securities Report, 99th period (FY2025, filed 22 Jun 2026) (disclosure2dl.edinet-fsa.go.jp)
  2. MGC Annual Securities Report, 98th period (FY2024, filed 24 Jun 2025) (disclosure2dl.edinet-fsa.go.jp)
  3. MGC Annual Securities Report, 97th period (FY2023, filed 25 Jun 2024) (disclosure2dl.edinet-fsa.go.jp)
  4. MGC Extraordinary Report, 11 Nov 2025 (MSCN impairment) (disclosure2dl.edinet-fsa.go.jp)
  5. MGC Q3 FY2023 Quarterly Report (JSP deconsolidation) (disclosure2dl.edinet-fsa.go.jp)
  6. FY2024 tanshin (12 May 2025) (www2.jpx.co.jp)
  7. Q1 FY2025 tanshin (7 Aug 2025) (www2.jpx.co.jp)
  8. Q1/Q2/Q3 FY2024 tanshin · www2.jpx.co.jp · www2.jpx.co.jp
  9. FY2022 tanshin (12 May 2023) (www2.jpx.co.jp)
  10. Representative director change (3 Feb 2025) (www2.jpx.co.jp)
  11. MEP additional acquisition (8 Feb 2022) (www2.jpx.co.jp)
  12. Buyback resolutions/completions (Nov 2023; Feb 2025) · www2.jpx.co.jp
  13. Formalin absorption-type split (12 May 2023) (www2.jpx.co.jp)
  14. S&P Global Market Intelligence via StockAnalysis (income statement, balance sheet, cash flow, statistics) (stockanalysis.com)
  15. ENVALITH company and segment pages · envalith.com · envalith.com
  16. Kabuyoho (IFIS consensus, valuation) (kabuyoho.jp)
  17. Monex Scouter (Q1 FY2026 vs consensus) (scouter.monex.co.jp)
  18. Yahoo! Finance Japan (Q1 FY2026 summary) (finance.yahoo.co.jp)
  19. Matsui Securities (quarterly breakdown) (finance.matsui.co.jp)
  20. Quartr investor presentation summary (3 Jul 2026) (quartr.com)
  21. FilingReader (FY2025 results summary, 13 May 2026) (filingreader.com)
  22. chemXplore (MSCN discontinuation; Kashima PC) · chemxplore.com
  23. ALCHEMPro / Tank Terminals (Kashima PC closure) (alchempro.com)
  24. Chemical Engineering (Thai BT expansion) (chemengonline.com)
  25. roic.ai company profile (Transition Industries offtake; product list) (roic.ai)
  26. gyokaidigest (FY2025 and Q3 FY2025 summaries) (gyokaidigest.com)
  27. the-shashi.com (CEO history, segment history, long-term history) · the-shashi.com · the-shashi.com
  28. EDINET DB (peer benchmark, large-holding data) (edinetdb.jp)
  29. crex-data (FY2024 analysis; JSP effect; Sharebeing) (crex-data.com)
  30. J-LIC (auditor, listing history) (j-lic.com)
  31. Mynavi corporate profile (plants, parent figures) (job.mynavi.jp)
  32. Simply Wall St (FY2024 earnings vs consensus) (simplywall.st)
  33. SustainabilityReports.com (integrated report summaries) (sustainabilityreports.com)
  34. DitchCarbon (emissions estimate) (ditchcarbon.com)
  35. Mitsubishi Chemical Group FY2025 earnings call (peer revenue) (roic.ai)
  36. JSP Corporation disclosures (Oct 2023 self-tender) (zonebourse.com)

Primary filings

Secondary sources

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.